It is of great significance to carry out the consistency evaluation of the quality and efficacy of generic drugs, which can enhance the brand value of products and enhance the discourse power of product markets, which has been paid more and more attention
by pharmaceutical companies.
Under the background of the normalization of centralized procurement, the evaluation of generic drugs is regarded as the "ticket" for pharmaceutical companies to participate in centralized procurement, further forcing pharmaceutical companies to cohesion and accelerate the consistency evaluation of
generic drugs.
On December 20, Lisheng Pharmaceutical replied to investors on the investor relations platform that the company will continue to maintain the intensity of R&D investment in 2023 and accelerate the development of 10 consistency evaluation projects, but the specific investment will be determined according to the progress of specific projects
.
According to reports, Lisheng Pharmaceutical focuses on the pharmaceutical and health industry, the company and its wholly-owned subsidiaries have varieties involving cardiovascular and cerebrovascular, anti-infection, antipyretic and analgesic and other 15 categories of more than 240 drug approval numbers, the main products are Shoubishan ® indapamide tablets, three fish ® positive pain tablets, cefdinil ® dispersible tablets, friendly ® hemp seed softgels, pine double ® cleansing agent, biochemical nalheparin calcium injection, biochemical ® ® hydrocortisone sodium suprefinate freeze-dried powder needle and sodium bicarbonate tablets, gastric tablets, vitamin tablet series products, etc
。
Lisheng Pharmaceutical has been actively promoting the consistency evaluation of generic drugs, and a number of drugs have been evaluated
since 2022.
For example, on December 6, it was announced that the 0.
2g specification of the company's metronidazole tablets passed the consistency evaluation
of generic drug quality and efficacy.
Metronidazole tablets are used to treat and prevent infections identified or suspected to be caused by anaerobic bacteria; In September, the announcement announced that the two drugs with folic acid tablets 5mg specification and hydrochlorothiazide tablet 25mg specification passed the consistency evaluation of quality and efficacy of generic drugs; In May, the company's donepezil hydrochloride tablets 5mg passed the quality and efficacy consistency evaluation of generic drugs; In April, the company announced that the company's compound sulfamethoxazole tablets sulfamethoxazole 0.
4g, trimethoprim 80mg specifications passed the quality and efficacy consistency evaluation of generic drugs.
.
.
Lisheng Pharmaceutical said on the investor interactive platform on December 14 that the company currently has a total of 15 specifications for drugs that have passed the consistency evaluation
.
Behind the successive reviews, it is inseparable from continuous research and development
.
Lisheng Pharmaceutical attaches great importance to R&D investment, and the R&D investment in 2021 will be 104 million yuan, a year-on-year increase of 35.
71%; The proportion of R&D investment in operating income was 9.
53%, an increase of 2.
81 percentage points
over the same period of the previous year.
The company said on the investor interactive platform in June that the company's research and development mainly involves four major aspects, including the input of quality and efficacy consistency evaluation, DNP, PNP, HJP and other 9 projects are under review, and other projects are advancing
as planned.
In addition, it includes: high-end generic drug varieties with technical barriers, YDP has carried out clinical trials, and the other 4 projects are advancing as planned; Cardiovascular and cerebrovascular medication, XAP is under review, and the other 3 projects are advancing as planned; API projects, BHY, FBY are under review, and the other 4 projects are advancing
as planned.
According to the third quarterly report of 2022, the company achieved main revenue of 902 million yuan, a year-on-year increase of 7.
94%; net profit attributable to owners was RMB113 million, up 15.
26% year-on-year; Non-net profit was RMB112 million, up 18.
83% year-on-year; Among them, in the third quarter of 2022, the company's main revenue in a single quarter was 287 million yuan, a year-on-year increase of 15.
69%; The net profit attributable to the parent in a single quarter was 40.
6698 million yuan, an increase of 11.
53% over the same period last year; The non-net profit in a single quarter was 40.
664 million yuan, up 13.
61%
from the same period last year.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
